Biden’s Judicial Appointment Race Against Time as 2024 Elections Approach
As the United States braces for the 2024 elections, President Joe Biden faces a crucial period in shaping the judicial landscape, contending with the prolific [more…]
Guy on Rocks: Uranium boom in ’24? We’ll smoke to that…
‘Guy on Rocks’ is a Stockhead series looking at the significant happenings of the resources market each week. Former geologist and experienced stockbroker Guy Le [more…]
Confessions of a Day Trader: Thanks WiseTech – we’re putting in a pool!
Each week, Stockhead’s resident day trader gives us a peek at the highs and lows of his trading diary and hints at what might be [more…]
Dr Boreham’s End-of-Year ASX Biotech report card
If the biotech sector were a classroom, the teacher’s end-of-year report card would read something like: “a patchy but solid effort in trying conditions, with [more…]
Emission Control: Will nuclear energy have a place in Australia’s grid future?
A new report by CSIRO and AEMO has found that new build costs for electric generation, energy storage and hydrogen production in Australia have stabilised [more…]
Hot Money Monday: Adbri and Comet Ridge have all the momentum right now
Momentum investing works on the theory that strong stocks will continue to rise in price, while weak stocks will continue to decline. On the up [more…]
Part 1: ASX biotechs with catalysts looking to pop in 2024
Neuren set to uphold momentum in 2024 as front-runner among biotechs with catalysts next year Dimerix’s first analysis outcome for its Phase 3 trial of [more…]
Rise and Shine: Everything you need to know before the ASX opens
On Stockhead today, Dr Boreham’s End-of-Year ASX report card, who’s riding momentum into ’24, and biotechs with catalysts looking to pop. But first, the day [more…]
SUNDAY ROAST: The stocks that lit a fire under our experts this week
Luke Winchester CIO, Merewether Capital The big question: Will 2024 be the year of micro and small caps? “At the risk of being a barber [more…]
CRITERION: Missed the Pro Medicus boat? These cheaper alternatives scan well
Have investors in one of Australia’s most dazzling home-grown ASX success stories missed the boat? Now worth just shy of $10 billion, the US-focused diagnostic [more…]
